{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=74", "query": { "intervention": "Injectable Placebo", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 4220, "total_pages": 422, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=75&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=73&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T16:35:24.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01061736", "title": "Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1675, "start_date": "2010-03", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 45, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061736" }, { "nct_id": "NCT02401737", "title": "Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "NVR 3-778", "type": "DRUG" }, { "name": "Placebo for NVR 3-778", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novira Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 58, "start_date": "2015-01-31", "completion_date": "2016-05-18", "has_results": false, "last_update_posted_date": "2017-10-18", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 4, "location_summary": "Costa Mesa, California • Pasadena, California • San Diego, California + 1 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401737" }, { "nct_id": "NCT05293171", "title": "Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "1.25 mg/kg BL-8040 + BL-8040-matching placebo", "type": "DRUG" }, { "name": "2 mg/kg BL-8040", "type": "DRUG" }, { "name": "BL-8040-matching placebo", "type": "DRUG" }, { "name": "400 mg Moxifloxacin (1x400 mg tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2021-06-11", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293171" }, { "nct_id": "NCT01097096", "title": "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "CAD106", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Alum", "type": "BIOLOGICAL" }, { "name": "MF59", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "85 Years", "sex": "ALL", "summary": "Up to 85 Years" }, "enrollment_count": 177, "start_date": "2010-03", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2021-03-05", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 5, "location_summary": "Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Eatontown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01097096" }, { "nct_id": "NCT02826603", "title": "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1114, "start_date": "2016-06-22", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 123, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826603" }, { "nct_id": "NCT07433023", "title": "tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cerebral Palsy" ], "interventions": [ { "name": "tSCS", "type": "OTHER" }, { "name": "5-Azacitidine", "type": "DRUG" }, { "name": "Mannitol", "type": "DRUG" }, { "name": "Functional Activity Training", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Shirley Ryan AbilityLab", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 80, "start_date": "2026-05-28", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07433023" }, { "nct_id": "NCT02053727", "title": "Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis", "Chronic Hepatitis B" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2018-06-12", "has_results": false, "last_update_posted_date": "2020-11-16", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02053727" }, { "nct_id": "NCT00865566", "title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA plasmid vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant adenoviral serotype 5 (rAD5) vector vaccine", "type": "BIOLOGICAL" }, { "name": "DNA vaccine placebo", "type": "BIOLOGICAL" }, { "name": "HIV-1 recombinant adenovirus vaccine placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 2504, "start_date": "2009-05", "completion_date": "2017-10-06", "has_results": true, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865566" }, { "nct_id": "NCT00414141", "title": "Efficacy and Safety/Tolerability of Grass MATA MPL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type I Hypersensitivity" ], "interventions": [ { "name": "Grass MATA MPL", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allergy Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 1028, "start_date": "2006-11", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2010-06-17", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 65, "location_summary": "Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414141" }, { "nct_id": "NCT06005441", "title": "A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Subcutaneous Fat" ], "interventions": [ { "name": "CBL-514 injection", "type": "DRUG" }, { "name": "CBL-A1 Injection", "type": "DRUG" }, { "name": "CBL-A2 Injection", "type": "DRUG" }, { "name": "0.9% Sodium Chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Caliway Biopharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 173, "start_date": "2023-11-10", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-11-02T16:35:24.222Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005441" } ] }